Oncology Views & Analysis

Views & Analysis

Oncology

ASCO 2023 – Martin Vogel and Edmond Chan

In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.

Oncology

ASCO 2023 – Corina Dutcus

At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major

Oncology

Science demands more patient centricity in oncology research

It’s simple: a clinical trial health system that enrols more patients will lead to faster treatment advances and, therefore, better outcomes for people with cancer.1 But, as it s

Oncology

Why are rates of HPV vaccination declining globally?

Despite the world possessing effective vaccines against HPV, rates of immunisation are actually falling in lower- and middle-income countries.

Oncology

ASCO 2023 – Arun Krishna

With a 51% reduction in deaths, AstraZeneca’s ADAURA trial was one of the breakout stories of this year’s ASCO.

Oncology

Sanofi is calling for a comprehensive, UK guideline to impro...

Non-melanoma skin cancer (NMSC) is the most common cancer in the UK, with more than 155,000 cases of NMSC reported in the UK every year.1,2 However, NMSC is significantly under-r

ASCO 2023 – Martin Vogel and Edmond Chan

ASCO 2023 – Corina Dutcus

Science demands more patient centricity in oncology research

Why are rates of HPV vaccination declining globally?

ASCO 2023 – Arun Krishna

Sanofi is calling for a comprehensive, UK guideline to impro...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Views & Analysis

Editor's Picks